KOL Perception on Migraine Management: How CGRP Therapies, AI, and Precision Medicine Are Transforming Migraine Care
Insights from 25 U.S. Key Opinion Leaders on CGRP-targeted therapies, precision medicine, AI-supported clinical decision making, digital therapeutics, biomarker research, remote patient monitoring, and the future of migraine management.
To understand expert perspectives on evolving migraine management, adoption of CGRP-targeted therapies, precision medicine, AI-supported clinical decision making, digital therapeutics, biomarker research, implementation challenges, and the future direction of migraine care.
CGRP Therapies, AI, and Precision Medicine Are Redefining Migraine Management
Migraine remains one of the leading causes of disability worldwide despite significant therapeutic advances. Over the past five years, the emergence of CGRP-targeted therapies, digital health technologies, and precision medicine has fundamentally changed the treatment landscape while creating new opportunities for more personalized patient care.
Although clinical outcomes have improved, healthcare providers continue to face challenges related to delayed diagnosis, treatment accessibility, reimbursement, variability in patient response, and long-term disease management. Artificial intelligence, biomarker research, remote patient monitoring, and digital therapeutics are expected to play an increasingly important role in optimizing migraine care over the coming years.
To better understand these evolving priorities, SPER Market Research conducted a survey among 25 U.S. Key Opinion Leaders to capture expert perspectives on CGRP therapies, precision medicine, biomarker-guided treatment, AI-powered migraine management, digital health technologies, adoption barriers, and the future of migraine care.
Neurology experts emphasize CGRP-targeted therapies, precision medicine, AI-powered clinical decision support, digital therapeutics, biomarker research, and remote patient monitoring to improve migraine outcomes.
CGRP therapies, AI-driven clinical decision support, precision medicine, wearable health technologies, digital therapeutics, and predictive analytics are expected to define the next generation of migraine management.
Key Survey Highlights
U.S. migraine Key Opinion Leaders demonstrate strong confidence in CGRP-targeted therapies, precision medicine, AI-supported clinical decision making, and digital health technologies as the future of migraine management.
Reported a high or very high need for continued innovation in migraine management.
Identified CGRP-targeted therapies as the most transformative advancement in migraine treatment during the past five years.
Expect substantial growth in AI-supported care, precision medicine, digital therapeutics, and remote patient monitoring within five years.
Remain optimistic about the future of migraine management over the next decade.
Migraine management continues to face significant clinical and implementation challenges
Despite major advances in migraine therapeutics, many patients continue to experience delayed diagnosis, inconsistent treatment response, limited access to advanced therapies, and long-term disease burden. Experts believe continued innovation remains essential to improving patient outcomes.
The survey found that 92% of experts believe continued innovation is highly necessary, while 80% feel that current treatment options are only partially adequate for addressing patient needs.
These findings reinforce the growing importance of CGRP-targeted therapies, biomarker-guided precision medicine, AI-powered clinical decision support, digital therapeutics, and remote patient monitoring in shaping the future of migraine care.
Variable treatment response
Patients respond differently to available migraine therapies, making treatment optimization challenging.
Limited predictive biomarkers
Reliable biomarkers are still needed to identify the most effective therapy for individual patients.
Delayed diagnosis
Delayed recognition of migraine and inconsistent clinical pathways continue to affect patient outcomes.
Access to advanced therapies
Insurance restrictions, reimbursement policies, and prior authorization requirements continue to limit access.
AI integration
Successfully integrating AI-supported decision making and digital therapeutics into routine clinical practice requires clinician confidence and interoperability.
Long-term disease management
Improving long-term monitoring, adherence, and personalized treatment strategies remains a major priority for migraine care.
Survey Results Summary
The migraine KOL survey provides valuable insights into CGRP-targeted therapies, precision medicine, biomarker-guided treatment, AI-supported clinical decision making, digital therapeutics, remote patient monitoring, and the future direction of migraine management.
Remain optimistic that CGRP therapies, precision medicine, AI-powered clinical decision support, and digital health technologies will significantly transform migraine care over the next decade.
Believe continued innovation remains essential for improving migraine management.
Believe current migraine therapies are only partially adequate for addressing patient needs.
Consider biomarkers and personalized medicine extremely important for optimizing migraine treatment decisions.
Expect significant expansion of CGRP therapies, AI-supported care, digital therapeutics, and remote monitoring within five years.
Most Common Response by Question
Continued innovation remains essential
Most experts believe migraine management still requires substantial therapeutic and technological innovation.
Current therapies are only partially adequate
Most KOLs believe further innovation is required to improve long-term migraine outcomes.
CGRP-targeted therapies lead innovation
Monoclonal antibodies and gepants were identified as the most significant advancement in migraine care.
Biomarkers are critical
Precision medicine and biomarkers are considered essential for future treatment optimization.
AI and CGRP therapies will rapidly expand
Most experts expect rapid adoption of AI-supported care, digital therapeutics, CGRP therapies, and remote monitoring.
Cost and reimbursement remain major barriers
High treatment costs, insurance restrictions, and prior authorization requirements continue to limit adoption.
Digital health and AI will improve outcomes
AI, digital health technologies, predictive analytics, and remote monitoring are expected to improve migraine outcomes.
Future outlook remains highly optimistic
Experts are confident that CGRP therapies, AI, precision medicine, and digital health will redefine migraine management.
Q5 – Q8
The Future of Migraine Management Is Personalized, Predictive, and Technology-Driven
This migraine KOL survey demonstrates that migraine management is entering a new era driven by CGRP-targeted therapies, precision medicine, artificial intelligence, biomarker-guided treatment, and digital health technologies. Insights gathered from 25 U.S. Key Opinion Leaders highlight growing confidence that personalized treatment strategies and AI-enabled clinical decision support will improve patient outcomes while reducing the burden of migraine.
For pharmaceutical companies, healthcare providers, digital health innovators, biotechnology firms, and investors, these findings provide valuable strategic direction for future product development and market expansion. Experts consistently identified CGRP-targeted therapies, AI-powered clinical decision support, biomarker research, predictive analytics, and remote patient monitoring as the innovations most likely to transform migraine care.
As adoption of targeted biologics, AI-supported care, digital therapeutics, precision medicine, and connected healthcare platforms continues to accelerate, organizations that improve affordability, reimbursement, access to specialist care, and patient-centered treatment pathways will be best positioned to shape the future of migraine management.
Strategic Takeaway
Organizations investing in CGRP-targeted therapies, AI-powered clinical decision support, biomarker-guided precision medicine, digital therapeutics, and remote patient monitoring will gain a competitive advantage as migraine management becomes increasingly personalized, predictive, and data-driven.
